Overall, the massive legislation coronavirus that passed the Senate and is headed to a House vote and then President Trump's desk is a mixed blessing for the pharmaceutical industry, containing an important proviso related to drug pricing, but missing several potentially significant policy changes that were included in draft legislation at the beginning of the process. Below is a look at some of the major provisions in various versions of the bill; manufacturing elements of the legislation will be addressed in a subsequent table.
More from Legislation
- • By
With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."
- • By
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
- • By
US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.
- • By
Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.






